IntelGenx Technologies Corp. (IGX.TO)

0.2150 +0.0150 (+7.50%) As of 11:32AM EDT. Market open.

IntelGenx Technologies Corp.

6420 Abrams
Ville Saint Laurent
Montreal, QC H4S 1Y2
Canada
514 331 7440
https://www.intelgenx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dwight Gorham	Chief Executive Officer	315k	N/A	1958
Mr. André Godin C.A., CPA, CA, CPA	President & CFO	357.44k	N/A	1964
Mr. Tommy Kenny J.D., L.L.B., M.Sc.	Senior VP & General Counsel	208.51k	N/A	1987
Ms. Nadine Paiement M.Sc.	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	213.81k	N/A	1977
Ms. Karen Kalayajian CPA	Vice President of Finance & Administration	N/A	N/A	1980
Stephen Kilmer	Investor Relations Officer	N/A	N/A	N/A
Ms. Ingrid Zerbe	Corporate Secretary	N/A	N/A	1954
Zenoz Nina Pourhassan	VP of Quality Operations of Subsidiary	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Corporate Governance

IntelGenx Technologies Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.